Anzeige
Meldung des Tages: Warum Kupfer und Silber aus Nevada plötzlich wieder im Fokus stehen könnten
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht Alle
Zurück
Weiter
1 2 3 4 5 6
Antworten | Hot-Stocks-Forum Übersicht Alle
Zurück
Weiter 1 2 3 4 5 6
Ein Milliarden Dollar Unternehmen wurde geboren?
Beiträge:
138
Zugriffe: 26.693 / Heute: 7
Zugriffe: 26.693 / Heute: 7
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +99,62%
Xtrackers CSI500 Swap UCITS ETF 1C
Perf. 12M: +56,55%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +55,77%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +55,58%
Xtrackers MSCI EM Latin America ESG Swap UCITS ETF 1C
Perf. 12M: +50,08%
Der Handel mit AMBS ist in Berlin beendet worden.
Nur die ISIN-Nummer geändert, gültig ab: 13. Dezember. 2012
Seite 1
Publication_038570.doc
Bekanntmachung
VERÄNDERUNGEN / CHANGES
Mit wirkung vom / gültig ab: 13. Dezember 2012
Name:
Amarantus BIOSCIE.
WKN:
A1JJ8L
ISIN:
US02300Q1058
Veränderung /
Ändern:
ISIN-Tausch
neue ISIN:
US02300T1097
neue WKN:
A1J9ZB
Name:
Prodigy Gold Inc
WKN:
A1H5YZ
ISIN:
CA74283A1003
Veränderung /
Ändern:
Fusion in Würfel Argonaut Gold Inc. im Verhältnis: 1 ST: 0,1042 ST in Aktien
der Argonaut Gold Inc. zzgl., Betrag:. CD 0,0001 WKN nach Tausch:, ISIN
nach Tausch:
neuer Bezeichnung
Argonaut Gold Inc
neue ISIN:
CA04016A1012
neue WKN:
A1C70D
Markieren
: Freiverkehr - variabel
Skontroführer
: 1172 mwb fairtrade Wertpapierhandelsbank AG
Berlin, den 12. Dezember 2012
Geschäftsführung DER BÖRSE BERLIN
Nur die ISIN-Nummer geändert, gültig ab: 13. Dezember. 2012
Seite 1
Publication_038570.doc
Bekanntmachung
VERÄNDERUNGEN / CHANGES
Mit wirkung vom / gültig ab: 13. Dezember 2012
Name:
Amarantus BIOSCIE.
WKN:
A1JJ8L
ISIN:
US02300Q1058
Veränderung /
Ändern:
ISIN-Tausch
neue ISIN:
US02300T1097
neue WKN:
A1J9ZB
Name:
Prodigy Gold Inc
WKN:
A1H5YZ
ISIN:
CA74283A1003
Veränderung /
Ändern:
Fusion in Würfel Argonaut Gold Inc. im Verhältnis: 1 ST: 0,1042 ST in Aktien
der Argonaut Gold Inc. zzgl., Betrag:. CD 0,0001 WKN nach Tausch:, ISIN
nach Tausch:
neuer Bezeichnung
Argonaut Gold Inc
neue ISIN:
CA04016A1012
neue WKN:
A1C70D
Markieren
: Freiverkehr - variabel
Skontroführer
: 1172 mwb fairtrade Wertpapierhandelsbank AG
Berlin, den 12. Dezember 2012
Geschäftsführung DER BÖRSE BERLIN
Kann weder in Berlin noch USA Order aufgeben was soll das Order wurde abgewiesen scheiß Postbank
wieder handeln, da ISIN Nummer gerade geändert wird!
Ok danke warte ich mal ab aber warum geht USA nicht
Interessanter Artikel:
MANF: Arresting cell death in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and more
www.thechairmansblog.com/...ury-cardiac-ischemia-and-more.html
MANF: Arresting cell death in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and more
www.thechairmansblog.com/...ury-cardiac-ischemia-and-more.html
Amarantus BioScience Licenses LymPro Alzheimer's Disease Diagnostic Blood Test
ih.advfn.com/...pid=nmona&article=55465450&symbol=AMBS
ih.advfn.com/...pid=nmona&article=55465450&symbol=AMBS
Artikel / Bericht ist vom 10.12.12. Stelle diesen einfach mal hier rein auf die Gefahr, daß dieser hier schon mal gepostet wurde. Grüße an alle investierten und ein schönes WE.
Grüße aus dem Remstal ;)
MANF: Arresting cell death in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and more
Innovation is difficult and risky. In biotechnology, you can add long and expensive to the list of challenges. On the upside, with the right technology and strategy, biotechnology innovations have the power to improve and prolong the lives of millions of people who suffer from disease, while generating revenues and value for shareholders.
Here at Amarantus, we are innovators in the field of Programmed Cell Death, also known as Apoptosis. Our lead drug candidate (Mesencephalic-Astrocyte-derived Neurotrophic Factor) MANF is a first-in-class therapeutic protein that mitigates apoptosis by improving the protein-folding process inside the cell. MANF is currently in pre-clinical development for a range of indications. Our primary focus is on developing MANF as a new disease-modifying treatment for Parkinson’s disease. We also have programs in Traumatic Brain Injury and Cardiac Ischemia, and have initiated an effort to identify a suitable orphan drug indication to pursue MANF’s further development. Because MANF acts at such a fundamental cellular level, it is likely to have applications across a broad range of currently unaddressed disease indications.
Amarantus management has been following the evolution of the biopharmaceutical space and we’ve developed our business model around important themes that are reshaping the way innovative products get developed in this new economy. Below are what we believe to be the most important trends in the industry:
1.Technology is not enough; you must build a business. We are focused on building a business, not a science project. To that end, we are evaluating complementary therapeutic assets in mid-stage clinical development to add to our pipeline to reduce time to market as we prepare for a national exchange up-listing. MANF is the centerpiece of our business, and we believe we can attract strong assets around it because of MANF’s vast potential. To this end, the Company has attracted a world-class team of advisors to give us the expertise to guide our business direction and diversify our pipeline.
2.Intellectual property is what big companies are willing to pay for. Our patent portfolio around MANF is extensive and robust. We recently won a patent challenge to our key intellectual property in Europe where the courts asserted that our IP covered not only MANF, but also proteins that closely resemble MANF. We are in a very strong negotiating position with any company that wants access to MANF.
3.Targeted medicines are what regulators are looking for. Amarantus in-licensed a clinical-stage Parkinson’s diagnostic program called NuroPro that will gives us a competitive advantage as we seek to prove that MANF has a ‘disease-modifying’ effect in Parkinson’s. This approach separates Amarantus from competitors because we are focusing on both therapeutics and diagnostics to help manage the disease.
4.Today’s business model is about partnerships. We have developed a partnering business model that is based on the belief that we must maximize our internal strengths, while leveraging the strengths of partners to best achieve our objectives. In order to maximize potential returns, the Company is establishing its partnership criteria with our advisors as we look at near-term value inflexions to achieve further value-building milestones.
I thank you for taking the time to read this letter and looking forward to communicating with you in the future.
Gerald E. Commissiong
President & Chief Executive
www.thechairmansblog.com/...ury-cardiac-ischemia-and-more.html
Grüße aus dem Remstal ;)
MANF: Arresting cell death in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and more
Innovation is difficult and risky. In biotechnology, you can add long and expensive to the list of challenges. On the upside, with the right technology and strategy, biotechnology innovations have the power to improve and prolong the lives of millions of people who suffer from disease, while generating revenues and value for shareholders.
Here at Amarantus, we are innovators in the field of Programmed Cell Death, also known as Apoptosis. Our lead drug candidate (Mesencephalic-Astrocyte-derived Neurotrophic Factor) MANF is a first-in-class therapeutic protein that mitigates apoptosis by improving the protein-folding process inside the cell. MANF is currently in pre-clinical development for a range of indications. Our primary focus is on developing MANF as a new disease-modifying treatment for Parkinson’s disease. We also have programs in Traumatic Brain Injury and Cardiac Ischemia, and have initiated an effort to identify a suitable orphan drug indication to pursue MANF’s further development. Because MANF acts at such a fundamental cellular level, it is likely to have applications across a broad range of currently unaddressed disease indications.
Amarantus management has been following the evolution of the biopharmaceutical space and we’ve developed our business model around important themes that are reshaping the way innovative products get developed in this new economy. Below are what we believe to be the most important trends in the industry:
1.Technology is not enough; you must build a business. We are focused on building a business, not a science project. To that end, we are evaluating complementary therapeutic assets in mid-stage clinical development to add to our pipeline to reduce time to market as we prepare for a national exchange up-listing. MANF is the centerpiece of our business, and we believe we can attract strong assets around it because of MANF’s vast potential. To this end, the Company has attracted a world-class team of advisors to give us the expertise to guide our business direction and diversify our pipeline.
2.Intellectual property is what big companies are willing to pay for. Our patent portfolio around MANF is extensive and robust. We recently won a patent challenge to our key intellectual property in Europe where the courts asserted that our IP covered not only MANF, but also proteins that closely resemble MANF. We are in a very strong negotiating position with any company that wants access to MANF.
3.Targeted medicines are what regulators are looking for. Amarantus in-licensed a clinical-stage Parkinson’s diagnostic program called NuroPro that will gives us a competitive advantage as we seek to prove that MANF has a ‘disease-modifying’ effect in Parkinson’s. This approach separates Amarantus from competitors because we are focusing on both therapeutics and diagnostics to help manage the disease.
4.Today’s business model is about partnerships. We have developed a partnering business model that is based on the belief that we must maximize our internal strengths, while leveraging the strengths of partners to best achieve our objectives. In order to maximize potential returns, the Company is establishing its partnership criteria with our advisors as we look at near-term value inflexions to achieve further value-building milestones.
I thank you for taking the time to read this letter and looking forward to communicating with you in the future.
Gerald E. Commissiong
President & Chief Executive
www.thechairmansblog.com/...ury-cardiac-ischemia-and-more.html
heute gehts weiter up
squeeze trigger report ist raus:
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
Approximately 300 Million Shares Shorted Since June 2011 Short Squeeze Has Begun As Stock Above $0.0379 SqueezeTrigger Price
BUYINS.NET,www.buyins.net,a leading provider of Regulation SHO compliance monitoring,short sale trading statistics and market integrity surveillance,has updated coverage on Amarantus BioSciences (OTCBB:AMBS) after releasing the latest short sale data through December 14,2012. The total aggregate number of shares shorted since June 2011 is approximately 300 million shares. Approximately 28.44% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.0379. A short squeeze has just begun as stock is above its SqueezeTrigger Price.
Click for original Report: www.buyins.com/reports/ambs11-2-12.pdf
squeeze trigger report ist raus:
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
Approximately 300 Million Shares Shorted Since June 2011 Short Squeeze Has Begun As Stock Above $0.0379 SqueezeTrigger Price
BUYINS.NET,www.buyins.net,a leading provider of Regulation SHO compliance monitoring,short sale trading statistics and market integrity surveillance,has updated coverage on Amarantus BioSciences (OTCBB:AMBS) after releasing the latest short sale data through December 14,2012. The total aggregate number of shares shorted since June 2011 is approximately 300 million shares. Approximately 28.44% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.0379. A short squeeze has just begun as stock is above its SqueezeTrigger Price.
Click for original Report: www.buyins.com/reports/ambs11-2-12.pdf
Sprechen Sie über die Plattform Drug, MANF!
Mögliche Korrekturen / Kuren für alle folgenden Schritte aus:
MANF für Erkrankungen Über GeneDecksing
OMIM Gen-Informationen: 601916 OMIM Erkrankungen: -
28 Krankheiten MANF:
rheumatoide Arthritis Parkinson Arthritis Karzinom
Lippenspalte Plattenepithelkarzinomen des Kopfes und Halses Cytomegalie-Infektion Hirnverletzung
Wachstumshormonmangel neurodegenerative Erkrankung Neuronitis DNA-Topoisomerase I
Plattenepithelkarzinom glaucomae Glaukom Nierenzellkarzinom Diabetes Alztimers
Twinning Parodontitis Speiseröhrenkrebs Eierstockkrebs
Bauchspeicheldrüsenkrebs Pankreatitis Prostatakrebs Ösophagitis
Retinitis Immundefizienz Hepatitis Prostatitis
Yup, würde ich sagen, wir haben eine BLOCK BUSTER in unseren Händen!
Mögliche Korrekturen / Kuren für alle folgenden Schritte aus:
MANF für Erkrankungen Über GeneDecksing
OMIM Gen-Informationen: 601916 OMIM Erkrankungen: -
28 Krankheiten MANF:
rheumatoide Arthritis Parkinson Arthritis Karzinom
Lippenspalte Plattenepithelkarzinomen des Kopfes und Halses Cytomegalie-Infektion Hirnverletzung
Wachstumshormonmangel neurodegenerative Erkrankung Neuronitis DNA-Topoisomerase I
Plattenepithelkarzinom glaucomae Glaukom Nierenzellkarzinom Diabetes Alztimers
Twinning Parodontitis Speiseröhrenkrebs Eierstockkrebs
Bauchspeicheldrüsenkrebs Pankreatitis Prostatakrebs Ösophagitis
Retinitis Immundefizienz Hepatitis Prostatitis
Yup, würde ich sagen, wir haben eine BLOCK BUSTER in unseren Händen!
Vielen Dank. So knapp 19 Millionen Aktien waren nicht zu liefern, wenn die Cusip Veränderung stattgefunden hat und neue Aktien geliefert werden gibt es eine enorme Menge, die abgedeckt werden muss, an der Spitze der regelmäßigen Shorts. Sehr bullish meiner Meinung nach. Mehr als das Volumen des gestrigen Aktivität, die schöne Gewinne gebracht. Sollte drängen uns letzten Widerstand. Wenn wir gute Daten aus vergleichenden Studie zu bald, dann wird dies schwer laufen (auch, härter als nur die Short-Squeeze). Viel Glück an alle in den Morgen!
Korrektur bis jetzt aus.
Vielleicht schließen wir ja noch im Plus heute.
Lassen wir uns überraschen :-))
Vielleicht schließen wir ja noch im Plus heute.
Lassen wir uns überraschen :-))
Epic Run Coming To Amarantus BioSciences (AMBS)_Institutional And Insider Accumulation_Big News Imminent Predicts Sierra World Equity Review
hab auch schon 350k geladen ;) und kaufe weiter zu! leider wurden 250k in meinem depot noch nicht auf die neu wkn umgeschrieben ;(
mein gefühl sagt mir das wir hier die 0,04 Dollar cent noch mal sehen, kann meine leider so oder so mommentan nicht handeln.Mache mir aber deswegen keine sorgen wir sitzen auf einer bombe.Wenn es so kommt lange ich in berlin wieder zu
Real-Time Best Bid & Ask
0.056 / 0.0585 (1 x 1)Why is size 1?Warum in berlin 0,07 zahlen
0.056 / 0.0585 (1 x 1)Why is size 1?Warum in berlin 0,07 zahlen
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Amarantus BioScience Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 1.672 | Amarantus Bioscence - WKN: A1J9ZB - MEGA NEWS $$$$ | Antont | Dr.Schuh | 25.04.21 03:33 | |
| 8 | Ein Milliarden Dollar Unternehmen wurde geboren? | sauerland1502 | krauty77 | 11.01.13 09:00 | ||
| 3 | 137 | Ein Milliarden Dollar Unternehmen wurde geboren? | sauerland1502 | wamu2009 | 02.01.13 16:28 | |
| 30 | Amarantus BioSciences in aller Munde | Balu4u | madeinhell | 18.12.12 08:29 |